Novo Nordisk A/s

Jesper Pass

Soeren Padkjaer

Jes Thorn Clausen

Søren Østergaard

Kasper Almholt

Pernille A Usher

Gustav Roeder

The present invention relates to a method of identifying urokinase plasminogen activator (uPA) antibodies. The invention also relates to antibodies that are capable of binding uPA and which are capable of reducing or inhibiting uPA activity. Furthermore, the invention relates to uses for such antibodies, such as therapeutic and pharmaceutical uses.

Antibodies that bind urokinase plasminogen activator

Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders.

Anti-human interleukin-20 antibodies

Growing community of inventors

Alleroed, Denmark

Jesper Pass